-
公开(公告)号:US06919379B2
公开(公告)日:2005-07-19
申请号:US10479763
申请日:2002-06-04
IPC分类号: C07D277/74 , A61K31/145 , A61K31/185 , A61P1/00 , A61P1/04 , A61P1/08 , A61P1/14 , A61P11/00 , A61P11/06 , A61P25/32 , A61P25/34 , A61P25/36 , C07C313/04 , C07D277/76 , A61K31/13 , C07C313/00
CPC分类号: C07C313/04 , A61K31/185
摘要: Novel compounds of formula (I) wherein R1 represents hydrogen; R2 represents hydroxy, fluoro, or an oxo group; R3 represents hydrogen; R4 represents hydrogen; and pharmaceutically acceptable salts, solvates, and the stereoisomers thereof, with the exception of the racemate of (3-amino-2-hydroxypropyl)sulphinic acid. The compounds are useful in therapy, especially for the treatment of reflux disease. The invention is also related to processes for their preparation, intermediates of said process and pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy
摘要翻译: 新的式(I)化合物,其中R 1代表氢; R 2表示羟基,氟或氧代基; R 3表示氢; R 4表示氢; 和其药学上可接受的盐,溶剂合物及其立体异构体,但(3-氨基-2-羟丙基)亚磺酸的外消旋物除外。 该化合物可用于治疗,特别是用于治疗反流疾病。 本发明还涉及其制备方法,所述方法的中间体和含有所述治疗活性化合物的药物组合物和所述活性化合物在治疗中的用途
-
公开(公告)号:US06716834B2
公开(公告)日:2004-04-06
申请号:US10276150
申请日:2002-11-12
申请人: Kjell Andersson , Tord Inghardt , Olle Karlsson , Marcel Linschoten , Jan-Erik Nyström , Gunnel Sundén
发明人: Kjell Andersson , Tord Inghardt , Olle Karlsson , Marcel Linschoten , Jan-Erik Nyström , Gunnel Sundén
IPC分类号: A61K31395
CPC分类号: C07D409/06 , C07D413/14
摘要: There is provided compounds of formulae I and IA wherein Y, R1, R2, R3, D1 and D2 have meanings given in the description which are useful as, or as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.
摘要翻译: 提供式I和IA的化合物,其中Y,R 1,R 2,R 3,D 1和D 2具有在本说明书中给出的含义,或作为 ,胰蛋白酶样蛋白酶如凝血酶的竞争性抑制剂,特别是在需要抑制凝血酶(例如血栓形成)或作为抗凝剂的条件的治疗中。
-
公开(公告)号:US07514560B2
公开(公告)日:2009-04-07
申请号:US11418819
申请日:2006-05-04
申请人: Karin Lövqvist , Gunnel Sundén , David Noreland , Ingvar Ymén
发明人: Karin Lövqvist , Gunnel Sundén , David Noreland , Ingvar Ymén
IPC分类号: C07D401/12
CPC分类号: A61K31/4439 , A61K31/454 , C07D401/12
摘要: The present invention relates to a novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, known under the generic name omeprazole. Further, the present invention also relates to the use of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H -benzimidazole for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it as well as processes for the preparation of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole.
摘要翻译: 本发明涉及5-甲氧基-2 - [[(4-甲氧基-3,5-二甲基-2-吡啶基)甲基]亚磺酰基] -1H-苯并咪唑的新型结晶形式,以通用名称奥美拉唑已知。 此外,本发明还涉及5-甲氧基-2 - [[(4-甲氧基-3,5-二甲基-2-吡啶基)甲基]亚磺酰基] -1H-苯并咪唑的新结晶形式用于处理 的胃肠道疾病,含有它的药物组合物以及制备5-甲氧基-2 - [[(4-甲氧基-3,5-二甲基-2-吡啶基)甲基]亚磺酰基] -1H的新结晶形式的方法 苯并咪唑。
-
公开(公告)号:US06384059B1
公开(公告)日:2002-05-07
申请号:US09640097
申请日:2000-08-15
申请人: Karin Lövqvist , Gunnel Sundén , David Noreland , Ingvar Ymén
发明人: Karin Lövqvist , Gunnel Sundén , David Noreland , Ingvar Ymén
IPC分类号: A61K314439
CPC分类号: C07D401/12 , A61K31/4439 , A61K31/454
摘要: The present invention relates to a novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl-1H-benzimidazole, known under the generic name omeprazole. Further, the present invention also relates to the use of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it as well as processes for the preparation of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole.
摘要翻译: 本发明涉及以通用名奥美拉唑公知的5-甲氧基-2 - [[(4-甲氧基-3,5-二甲基-2-吡啶基)甲基]亚磺酰基-1H-苯并咪唑的新结晶形式。 此外,本发明还涉及5-甲氧基-2 - [[(4-甲氧基-3,5-二甲基-2-吡啶基)甲基]亚磺酰基] -1H-苯并咪唑的新结晶形式用于处理 的胃肠道疾病,含有它的药物组合物以及制备5-甲氧基-2 - [[(4-甲氧基-3,5-二甲基-2-吡啶基)甲基]亚磺酰基] -1H的新结晶形式的方法 苯并咪唑。
-
-
-